Peapack, New Jersey 07977

  • HIV Infections


The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.


Inclusion Criteria Patients must have: - HIV infection. - Plasma HIV-1 levels greater than 10,000 copies/ml.



Primary Contact:


Backup Contact:


Location Contact:

Peapack, New Jersey 07977
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.